# Neutrophil Percentage–to-Albumin Ratio as a Novel Prognostic Biomarker in Adult Diffuse Gliomas: Retrospective Study Integrating 3 Machine Learning Models and Cox Regression

**Authors:** Congcong Zhu, Jiyang An, Lili Zhou

PMC · DOI: 10.2196/79945 · JMIR Medical Informatics · 2026-01-13

## TL;DR

This study introduces a new blood-based biomarker, NPAR, to predict outcomes in adult diffuse brain tumors using machine learning and survival analysis.

## Contribution

The first identification of preoperative neutrophil percentage–to-albumin ratio (NPAR) as a significant prognostic biomarker for adult diffuse gliomas using machine learning.

## Key findings

- NPAR, age, and platelet-to-mean platelet volume ratio were identified as independent prognostic factors for overall survival.
- The developed models showed strong predictive performance with concordance indices of 0.731 and 0.763 in training and validation cohorts.
- Risk stratification based on the model revealed significant survival differences between groups, supporting clinical applicability.

## Abstract

Adult-type diffuse glioma (ADG) is the most common primary malignant tumor of the central nervous system. Its highly invasive nature, marked heterogeneity, and resistance to therapy contribute to a high risk of recurrence and poor prognosis. At present, the lack of reliable prognostic tools poses a significant barrier to the development of individualized treatment strategies.

This study aimed to develop an effective prognostic model for ADG by integrating multiple machine learning algorithms, in order to enhance the precision of individualized clinical decision-making.

In this retrospective study, 160 newly diagnosed patients with ADG who underwent surgical resection and histopathological confirmation at our institution between June 2019 and September 2021 were included. A total of 32 variables, including clinical characteristics, molecular biomarkers, and preoperative hematological indicators, were collected. Overall survival (OS) and progression-free survival (PFS) were defined as the study endpoints. Feature selection was performed using least absolute shrinkage and selection operator regression, extreme gradient boosting, and random forest algorithms. Kaplan-Meier survival curves and log-rank tests were used for survival analysis. Multivariate Cox proportional hazards models were constructed to identify independent prognostic factors, and nomograms were developed accordingly. The model’s discriminative ability, calibration, and clinical utility were evaluated using the concordance index, area under the receiver operating characteristic curve (area under the curve), calibration plots, and Kaplan-Meier analysis.

Age, neutrophil percentage–to-albumin ratio (NPAR), and platelet-to-mean platelet volume ratio were identified as independent prognostic factors for OS, while age and NPAR were independent predictors for PFS (all P<.001). The prognostic models based on these variables demonstrated good predictive performance, with concordance index values of 0.731 and 0.763 for the training and validation cohorts in the OS model, respectively. The PFS model also showed robust performance. Area under the curve values and calibration curves further supported the models’ accuracy and stability. Risk stratification analysis revealed clear survival differences between risk groups (all P<.05), indicating strong clinical applicability.

This study is the first to identify preoperative NPAR as a significant prognostic biomarker for ADG using machine learning approaches. The prognostic model incorporating NPAR, platelet-to-mean platelet volume ratio, and age demonstrated favorable predictive performance, offering a novel perspective for accurate risk stratification and personalized treatment in patients with ADG.

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, OLIG2 (oligodendrocyte transcription factor 2) [NCBI Gene 10215] {aka BHLHB1, OLIGO2, PRKCBP2, RACK17, bHLHe19}, ATRX (ATRX chromatin remodeler) [NCBI Gene 546] {aka JMS, MRX52, RAD54, RAD54L, XH2, XNP}, CD34 (CD34 molecule) [NCBI Gene 947], RBFOX3 (RNA binding fox-1 homolog 3) [NCBI Gene 146713] {aka FOX-3, FOX3, HRNBP3, NEUN}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, SYNM (synemin) [NCBI Gene 23336] {aka DMN, SYN}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, MGMT (O-6-methylguanine-DNA methyltransferase) [NCBI Gene 4255]
- **Diseases:** astrocytoma (MESH:D001254), cardiac, hepatic, or renal dysfunction (MESH:D006331), breast and colorectal cancer (MESH:D001943), hypoalbuminemia (MESH:D034141), mental retardation syndrome (MESH:D008607), systemic disease (MESH:D034721), AISI (MESH:D007249), pneumonitis (MESH:D011014), ADG (MESH:D020339), NLR (MESH:D015467), Tumors of the Central Nervous System (MESH:D016543), diminished platelet (MESH:D015354), metastasis (MESH:D009362), mOS (MESH:D011475), PNI (MESH:D044342), death (MESH:D003643), immune dysfunction (MESH:D007154), LDH (MESH:C538133), alpha-thalassemia (MESH:D017085), cancers (MESH:D009369), neurological impairment (MESH:D009422), angiosarcoma (MESH:D006394), X-linked (MESH:C536424), alpha-thalassemia/mental retardation syndrome X-linked (MESH:C538258), cachexia (MESH:D002100), pancreatic and urological cancers (MESH:D010190), 19qLOH (MESH:C538311), infection (MESH:D007239), Glioma (MESH:D005910), T-cell dysfunction (MESH:C536780), glioblastoma (MESH:D005909)
- **Chemicals:** temozolomide (MESH:D000077204), alkylating (-), bevacizumab (MESH:D000068258)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** V600E, serine/threonine, R132, (AUC) at 1

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12848496/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12848496/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12848496/full.md

---
Source: https://tomesphere.com/paper/PMC12848496